Cerdelga
| Chemical Name | eliglustat |
| Dosage Form | Capsule (oral; 84mg) |
| Drug Class | Inhibitors |
| System | Blood, Musculoskeletal |
| Company | Sanofi-Aventis |
| Approval Year | 2014 |
Indication
- For the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6v extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.